China’s pharma industry saw a rise of 16.7% in overall deal activity during Q4 2018, when compared with the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 35 deals worth $1.29bn were announced in Q4 2018, compared to the last four-quarter average of 30 deals.

Venture financing was the leading category in the quarter with 21 deals which accounted for 60% of all deals.

In second place was M&A with 11 deals, followed by private equity with three transactions, respectively accounting for 31.4% and 8.6% of overall deal activity in the country’s pharma industry during the quarter.

In terms of value of deals, M&A was the leading deal category in China’s pharma industry with total deals worth $605.17m, while venture financing and private equity deals totalled $477.58m and $209.57m, respectively.

China pharma industry deals in Q4 2018: Top deals

The top five pharma deals accounted for 69.7% of the overall value during Q4 2018.

The combined value of the top five pharma industry deals stood at $901.27m, against the overall value of $1.29bn recorded for the quarter. The top announced China pharma industry deal tracked by GlobalData in Q4 2018 was Covis Pharma ‘s $371m asset transaction with AstraZeneca .

In second place was the $160m private equity deal with InnoCare Pharma by 3H Health Investment , Epiphron Capital Fund I , Loyal Valley Capital , Shanghai Jianxin Capital and Vivo Capital and in third place was China Industrial Asset Management , China Pacific Capital , Haier Capital and Legend Capital ‘s $136m venture financing of Shanghai Cell Therapy Group .

The $134.27m acquisition of Shandong Freda Medical Device by Lushang Property and Advantech Capital, China Venture Capital Fund Corporation, Heritage Provider Network , Janchor Partners , Orbimed Advisors and PAG (formerly Pacific Alliance Group)’s venture financing of Jiangsu Alphamab Biopharmaceuticals for $100m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

Verdict makes every effort to ensure the accuracy of its deals information. If you spot a mistake, or would like to notify us of a deal which should be included in this analysis, please email us at deals@globaldata.com

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.